Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®

May 2, 2011 By Bio-Medicine.Org

SAN DIEGO, May 2, 2011 /PRNewswire/ — Prometheus Laboratories
Inc., a specialty pharmaceutical and diagnostic company, today
announced that it has signed an exclusive agreement with WILEX AG
for commercialization rights in the United States for RENCAREX®
(girentuximab).  RENCAREX® is a Phase III product
candidate for adjuvant use in non-metastatic clear-cell renal cell
cancer (ccRCC).

Under the terms of the agreement, WILEX will receive $19.0
million upfront payments and development fees plus milestone
payments and royalties on U.S. net sales of RENCAREX®.  In
addition, Prometheus will co-fund a portion of the ongoing
development of RENCAREX®. The deal terms also include an
agreement whereby WILEX may be granted commercialization rights
outside of the United States, including but not limited to Europe,
to one of Prometheus’ marketed products or receive additional cash
payments of up to $20 million.

Professor Olaf G. Wilhelm, Chief Executive Officer of WILEX,
commented, “This is the deal we have been looking for, not only in
financial, but also in commercial and strategic terms. We are very
excited about WILEX’S new partnership with Prometheus since
Prometheus has a proven track record in commercializing
pharmaceutical and diagnostic products.”

“We are very pleased to enter into this partnership with WILEX
as we continue to build our oncology franchise,” said Joseph M.
Limber, President and Chief Executive Officer of Prometheus.
“RENCAREX® is a great strategic fit with our current oncology
portfolio in renal cell carcinoma. There is no product currently
approved in the United States for patients who could have
recurrence of ccRCC after a kidney resection.  We look forward
to working with WILEX to complete the development process and
commercialize RENCAREX® in the United States.”

About RENCAREX®

RENCAREX® (girentuximab) is a highly specific chimeric
monoclonal antibo

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech